Retina

According to Jeffrey Heier, MD, RGX-314 administered by subretinal injection was well tolerated. In addition, it was associated with dose-dependent increase in ocular protein expression and evidence of clinical benefit.

Nieraj Jain, MD, describes the investigations that led to the recent identification of this drug-related retinal toxicity and described the clinical features that support its diagnosis.

Speakers at AAO 2019 event describe journey leading to approval of the first gene therapy for a genetic disease.

Researchers demonstrate the feasibility of a surgical method that specifically targets the area of geographic atrophy for RPE replacement.

Genetic factors play a key role in the onset and progression of diabetic retinopathy, with 65 genes ifentified with several belonging to signaling pathways. 

Tool is empowering patients to understand disease, become more involved in their treatment.

Dr. Kaiser discusses how risuteganib fared in a phase II trial in patients with intermediate nonexudative AMD. 

ICYMI: Dr. Blinder compares the efficiencies between two surgical cutters

Eyes with persistent subretinal fluid fared better with visual acuity than eyes that were dry, according to the HARBOR Trial

Uveitic glaucoma presents a treatment challenge because of the need to control two conditions. Furthermore, side effects of conventional treatments for uveitis-corticosteroids and systemic immunomodulatory agents-limit their use.

Sixty-five genes identified with several belonging to signaling pathways

Amid the introduction of new technologies, device still playing critical role

Anatomic changes after RD might help determine best time for surgery

May provide better anatomic improvement, decreased DR severity scores

Ganglion, bipolar cells increase options for patients with late-stage retinal disease